Slideshow

Top 5 Diabetes Technologies for 2017

Author(s):

Veronica Hackethal MD

The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management. 

From the first-to-market hybrid closed loop technology for continuous glucose monitoring to the first cloud-connected injectable therapy delivery device available for home use, the slides above highlight 5 new technologies that won the Patient Care editor's choice for the best tech advances in 2017 for management of type 1 and type 2 diabetes. 

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Related Content
Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes | Image Credit: National Cancer Institute
January 7th 2025

Serum Uric Acid Levels Linked to Risk of Dyslipidemia in Type 2 Diabetes

Connor Iapoce
Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas | Image Credit: HCPLive
January 6th 2025

Diabetes Dialogue: Leveraging Smart Algorithms for Insulin Optimization with Eran Atlas

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes| Image Credit: Kenny Eliason/Unsplash
January 3rd 2025

GLP-1 RA Discontinuations Frequent in People with Obesity Without Diabetes

Connor Iapoce
Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials | Image Credit: HCPLive
January 2nd 2025

Diabetes Dialogue: Insights on INHALE-1 and CATALYST Trials

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Logo | Credit: US Food and Drug Administration
December 23rd 2024

FDA Approves Generic Once-Daily GLP-1 RA for Type 2 Diabetes in Pediatric, Adult Patients

Patrick Campbell
David Tak Wai Lui I Credit: ResearchGate
December 20th 2024

Study Shows a U-Shaped Association Between HDL-C, Major Adverse Cardiovascular Events

Chelsie Derman
© 2025 MJH Life Sciences

All rights reserved.